Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P)

Vaccine

Volumn 19, Issue 20-22, 2001, Pages 2862-2877

  Cafaro, Aurelio ^a   Titti, Fausto ^a   Fracasso, Claudio ^a   Maggiorella, M Teresa ^a   Baroncelli, Silvia ^a   Caputo, Antonella ^b   Goletti, Delia ^a   Borsetti, Alessandra ^a   Pace, Monica ^a   Fanales Belasio, Emanuele ^a   Ridolfi, Barbara ^a   Negri, Donatella R M ^a   Sernicola, Leonardo ^a   Belli, Roberto ^a   Corrias, Franco ^a   Macchia, Iole ^a   Leone, Pasqualina ^a   Michelini, Zuleika ^a   Ten Haaft, Peter ^c   Buttò, Stefano ^a   Verani, Paola ^a   Ensoli, Barbara ^a   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

CD8 T cells; HIV vaccine; Tat

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; EXPRESSION VECTOR; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; LONG TERM EXPOSURE; LYMPHOCYTE COUNT; MACACA; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS DETECTION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; DINUCLEOSIDE PHOSPHATES; DNA METHYLATION; GENE PRODUCTS, TAT; HIV ANTIBODIES; MACACA FASCICULARIS; VACCINATION; VACCINES, DNA;

EID: 0035815501     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00002-0     Document Type: Article

References (66)

1. AIDS vaccine development in primate models
2. Why do not have an HIV vaccine and how can we make one?
3. Novel strategies toward the development of an effective vaccine to prevent HIV infection or AIDS
4. Control of SHIV89.6P infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
5. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine
6. Vaccination with Rev and Tat against AIDS
7. The trans-activator gene of human T-lymphotropic virus type III (HTLV-III)
8. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein
9. The trans-activator gene of HTLV-III is essential for virus replication
10. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region
11. Tat protein of HIV-1 stimulates growth of AIDS-Kaposi's sarcoma-derived cells
12. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation
13. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp 120
14. Cellular uptake of the Tat protein from human immunodeficiency virus
15. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells
16. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis
17. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi's sarcoma and cytokine activated vascular cells induces adhesion of the same cell types by using integrin receptors recognizing the RGD aminoacid sequence
18. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the α5β1 and αvβ3 integrins and by mobilizing sequestered basic fibroblast growth factor
19. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma
20. IFN-γ induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: Implications for AIDS-Kaposi's sarcoma pathogenesis
21. Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells
22. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains
23. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein
24. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection
25. Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells
26. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness
27. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1
28. C-C chemokines, pivotal in protection against HIV type 1 infection
29. Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes
30. Introduction of soluble proteins into the MHC class-I pathway by conjugation to an HIV tat peptide
31. Cytotoxic T lymphocyte activity in children infected with HIV
32. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo
33. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1
34. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein
35. HIV-1 Rev and Tat specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS
36. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine
37. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
38. Immune recognition of foreign DNA: A cure for bioterrorism?
39. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
40. Expression and characterization of the trans-activator of HTLV-III/LAV virus
41. Rapid sequencing of the Sendai virus 6.8 kb large (L) gene through primer walking with an automated DNA sequencer
42. A recombinant prime, peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen
43. Cytotoxic T lymphocytes do not appear to select for mutations in an immunodominant epitope of simian immunodeficiency virus gag
44. Simultaneous measurement of NK cell cytotoxicity against two target cell lines labelled with fluorescent lanthanide chelates
45. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys
46. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
47. A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques
48. Perforin, Fas/Fas ligand, and TNF-α pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL
49. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes release gamma interferon, tumor necrosis factor alpha (TNF-α), and TNF-β when they encounter their target antigens
50. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact
51. Role of TNF-α in CD8+ cytotoxic T lymphocyte-mediated lysis
52. Determinants of disease in the simian immunodeficiency virus-infected rhesus macaque: Characterizing animals with low antibody responses and rapid progression
53. CD8+ cell-derived anti-human immunodeficiency virus inhibitory factor
54. Perspectives on the role of CD8+ cell suppressor factors and cytotoxic T lymphocytes during HIV infection
55. Noncytolytic CD8 T cell-mediated suppression of HIV replication
56. Controlling HIV pathogenesis: The role of the noncytotoxic anti-HIV response of CD8+ T cells
57. CD8+ cells from HIV-2-infected baboons control HIV replication
58. Inhibition of simian immunodeficiency virus (SIV) replication by CD8(+) T lymphocytes from macaques immunized with live attenuated SIV
59. Superinfection with human immunodeficiency virus type 2 can reactivate virus production in baboons but is contained by a CD8 T cell antiviral response
60. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
61. Generation of CD8 suppressor factor β chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques
62. An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status
63. CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual
64. Human Retroviruses and AIDS. A compilation and analysis of nucleic acids and amino acid sequences
65. Cellular cytotoxic response induced by DNA vaccination in HIV-1- infected patients